Use of an AI voice agent to prompt self-reported blood pressure readings helped to improve accuracy of blood pressure measures and patient outcomes in a group of majority ages 65 and older patients with high blood pressure.

Results from the FigHTN Phase 2 clinical trial showed baxdrostat, a new medication that inhibits the production of the hormone aldosterone, lowered systolic blood pressure by about 5% when added to the existing medications taken by people with chronic kidney disease and who also have uncontrolled high blood pressure.

An analysis of 25 years of the CDC WONDER database for death rates from hypertension-related kidney disease (also called hypertensive kidney disease or hypertensive renal disease) in the U.S. through 2023 found persistent differences across race, ethnicity, gender and region.

Despite their effectiveness in lowering sodium intake and managing blood pressure, salt substitutes were rarely used by people with high blood pressure, according to a review of almost 20 years of U.S. health survey data.